CD274 and non-small cell lung carcinoma: Here, we present results from the primary analysis of a randomized phase II study assessing the safety and efficacy of epacadostat plus pembrolizumab (combination) versus placebo plus pembrolizumab (control) in patients with metastatic NSCLC expressing high levels of PD-L1 (TPS ≥ 50%) (NCT03322540).